Company A-share Code: Shanghai Pharmaceuticals Holding Co.Ltd(601607) company abbreviation: Shanghai Pharmaceuticals Holding Co.Ltd(601607) company H-share Code: 02607 company abbreviation: Shanghai Pharmaceutical Shanghai Pharmaceuticals Holding Co.Ltd(601607)
Summary of annual report 2021
Section I important tips
1. The summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should go to Shanghai Stock Exchange: http://www.sse.com.cn. Stock exchange of Hong Kong: http://www.hkexnews.hk The website carefully reads the full text of the annual report. 2. The board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and completeness of the contents of the annual report, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 3. All directors of the company attend the board meeting. 4 PricewaterhouseCoopers Zhongtian Certified Public Accountants (special general partnership) issued a standard unqualified audit report for the company. 5. The profit distribution plan or the plan of converting accumulation fund into share capital in the reporting period adopted by the resolution of the board of directors
The company plans to distribute a cash dividend of 4.20 yuan (including tax) for every 10 shares to all shareholders. As of the disclosure date of this report, the total share capital including the number of exercised shares of the company’s equity incentive is 2842445936 shares. Based on this calculation, the total amount of cash dividends to be distributed is 11938279312 yuan (including tax), accounting for 23.44% of the consolidated net profit attributable to the shareholders of the listed company in the current year. After distribution, the company’s balance consolidated undistributed profit was 2740477074155 yuan. During the reporting period, no capital reserve will be converted into share capital.
On March 22, 2022, the company received the reply on approving Shanghai Pharmaceuticals Holding Co.Ltd(601607) non-public development of shares issued by China Securities Regulatory Commission, and disclosed the relevant announcement on the same day. Meanwhile, the first batch of options of the company’s 2019 stock option plan are in the vesting period. According to the foregoing, before the equity distribution registration date, the total share capital may change due to non-public offering and equity incentive exercise.
If the total share capital of the company changes between the date of equity distribution and the date of equity registration, the company plans to keep the amount of distribution per share unchanged and adjust the total profit distribution accordingly based on the total share capital on the date of equity distribution.
The above profit distribution plan needs to be submitted to the 2021 annual general meeting of the company for deliberation.
Section II basic information of the company
1 company profile
Company stock profile
Stock type stock exchange stock abbreviation stock abbreviation before stock code change
A-share Shanghai Stock Exchange Shanghai Pharmaceuticals Holding Co.Ltd(601607) Shanghai Pharmaceuticals Holding Co.Ltd(601607) 600849
H-share SEHK SHP 02607 not applicable
Contact person and contact information secretary of the board of directors securities affairs representative
Name: Chen Jinzhu, Lu Ye, sun Shiyi
Office address Shanghai Pharmaceuticals Holding Co.Ltd(601607) building, 200 Taicang Road, Shanghai
Tel. + 862163730908
E-mail [email protected]. [email protected].
2. Introduction to the company’s main business in the reporting period
(1) Development stage and cyclical characteristics of the company’s industry during the reporting period
The company is a large pharmaceutical industry group listed in Shanghai and Hong Kong. It is a core enterprise in the large health industry sector under the controlling shareholder of Shanghai real estate group. Its main business is pharmaceutical industry, distribution and retail, ranking a leading position in China. It has unique comprehensive advantages in the industrial chain, can share the sustainable growth opportunities of China Meheco Group Co.Ltd(600056) health industry to the greatest extent, and can produce synergy through resource sharing among business sectors. Pharmaceutical consumption has a rigid attribute, and the pharmaceutical industry shows the characteristics of weak periodicity. The pharmaceutical industry is a strategic industry related to the national economy and the people’s livelihood, economic development and national security. It is an important foundation for the construction of a healthy China. During the “14th five year plan” period, the accelerated evolution of the world’s great changes that have not been seen in a century and the beginning of China’s new journey of socialist modernization blend with each other. The covid-19 pneumonia epidemic has a wide and far-reaching impact, and the development of the pharmaceutical industry has entered a new stage of development, showing new characteristics:
1. A new round of technological change and cross-border integration accelerated. Breakthroughs have been made in the basic research and transformation application of new mechanisms and new target drugs. Biomedicine is deeply integrated with the new generation of information technology. The new generation of biotechnology represented by gene therapy and cell therapy is becoming more and more mature, which provides a broad space for the pharmaceutical industry to seize a new round of scientific and technological revolution and industrial transformation opportunities.
2. The global pharmaceutical pattern is facing adjustment. Since the outbreak of covid-19 pneumonia, countries have paid more and more attention to the strategic position of the pharmaceutical industry. At the same time, economic globalization has encountered a countercurrent, the reconstruction of the industrial chain and supply chain has accelerated, and a number of Chinese pharmaceutical enterprises extending to a higher value chain are expected to accelerate to become world leading pharmaceutical enterprises.
3. The new development stage brings new development opportunities to the pharmaceutical industry. With the acceleration of population aging, the construction of a healthy China has been promoted nationwide, the health consumption of residents has been upgraded, and the supply side structural reform of the pharmaceutical industry has been accelerated to better meet the needs of the people for a better life; China’s economy has turned to a high-quality development stage, and the pharmaceutical industry has accelerated quality reform, efficiency reform and power reform, so as to provide support for building a new development pattern with China’s big cycle as the main body and China’s international double cycle promoting each other.
On the whole, during the “14th five year plan” period, the pharmaceutical industry will enter a new stage of high-quality development of accelerating innovation driven development, promoting industrial chain modernization and integrating into the global industrial system at a higher level.
(2) Industry situation
During the reporting period, with the continuous improvement of covid-19 vaccination rate, the epidemic prevention and control in various countries and regions gradually normalized, the impact margin of covid-19 epidemic narrowed, and the operation of the pharmaceutical industry gradually returned to normal.
With the promotion of the national top-level design and relevant ministries and commissions, the “three medical” linkage reform continued to deepen. In terms of medicine, encouraging innovation and purchasing generic drugs with volume are still hot spots, and further promote the development of traditional Chinese medicine industry and rare disease drugs; In terms of medical insurance, we will continue to deepen the reform of payment methods, and further promote the sound development of the industry in combination with the dynamic adjustment of medical insurance catalogue, the normalization of volume procurement and the national medical insurance negotiation; In terms of medical treatment, we issued important policies such as the adjustment of the catalogue of essential drugs.
Category time department file content
Ministry of industry and information technology, NDRC
Commission, Ministry of science and technology, 1. During the 14th Five Year Plan period, the bank wide Ministry of Commerce and the health industry’s R & D investment increased by more than 10% annually;
The top-level plan is part 2022 / 01 / 30, and the national development plan for medical insurance industry. 2. Strengthen the clinical urgently needed rare drugs Bureau and the disease drug support capacity of the National Drug Administration. A number of political bureaus and national traditional Chinese medicine policies encourage enterprises to speed up the development of nine kinds of drugs, such as relevant product and drug administration.
Department joint release
From the “14th five year plan” period to 2025, 100 pharmaceutical wholesale and circulation 2021 / 10 / 21 the Ministry of commerce promotes the strong enterprise of pharmaceutical circulation, and the annual sales account for 98% of the total wholesale market with high-quality development of the pharmaceutical industry.
Notice on accelerating the development of traditional Chinese medicine, giving better play to the characteristics of traditional Chinese medicine and some advantages of the general office of the State Council in the development of traditional Chinese medicine on February 9, 2021, and promoting the policies and measures of traditional Chinese medicine and Western Medicine
The national medical security issued the guiding opinions on the development of medical insurance administration on specific measures to support good inheritance and development, 2021 / 12 / 31 Bureau, national inheritance and innovation of traditional Chinese medicine and good utilization of traditional Chinese medicine
It is proposed that China should realize the traceability of the whole process used in the management regulations of the State Food and Drug Administration on the vaccine industry on October 9, 2021 (soliciting small packaging units from production to use draft).
National essential drugs
On November 15, 2021, the catalogue management measures of the National Health Commission (revised the draft of dynamic revision of the catalogue of essential drugs) solicited adjustment.
see
The catalogue of national basic medical insurance, basic drugs, insurance, work-related injury insurance and a total of 74 kinds of drugs newly improved medical insurance was included in the catalogue of maternity insurance drugs of the National Medical Insurance Bureau on December 3, 2021, and 11 kinds of drugs were transferred out of the catalogue (2021). Among them, 67 kinds of exclusive drugs outside the catalogue were successfully negotiated.
On doing a good job in the country
Organize the centralized drug delivery, and put forward a series of requirements for the smooth volume procurement after the expiration of the purchase agreement. On November 4, 2021, the national medical insurance administration will continue to put forward a series of requirements after the expiration of the volume procurement agreement
Communication of subsequent work
Knowledge
The company actively integrated into the national strategy, correctly predicted the industry situation and prepared for a rainy day. On the one hand, over the years, the company has continuously strengthened the construction of academic brand, expanded market coverage, optimized market structure, and made more doctors and patients recognize it with wider coverage, better reputation and better curative effect
